Two Onc Docs
Sam and Karine
This is Sam and Karine, and we are Two Onc Docs! We both graduated from our Heme/Onc fellowships in 2021 and became board certified in both Hematology and Oncology. Our mission with Two Onc Docs is to create short board review episodes that you can listen to on your drive to work, while you make your morning coffee, or between pages on call. This is intended to be a supplement to other established board studying resources for busy trainees. *This podcast is intended to be an educational resource for health care providers.*
Episodes
Mentioned books
Jun 13, 2022 • 11min
Myelodysplastic Syndrome (MDS)
Today’s episode is focusing on what you need to know regarding myelodysplastic syndrome (MDS) - diagnosis, risk stratification and treatment options for low risk as well as high risk MDS.
Jun 6, 2022 • 11min
Anal Cancer
Topics discussed in this episode include rising cases of anal squamous cell carcinoma in the US, risk factors like HPV infection and smoking, diagnostic workup and staging of anal cancer, treatment regimens for different stages, alternative treatment options and surveillance protocol, and the role of immunotherapy in anal cancer treatment.
May 30, 2022 • 13min
Melanoma
This podcast discusses risk factors, diagnostic work-up, staging, and treatment options for melanoma. It covers excision margins, surgical management, and adjuvant therapy. The episode also explores staging criteria for metastatic melanoma, treatment options, side effects, and monitoring. Additionally, it mentions BRF and MEK inhibitors for metastatic melanoma, rare subtypes of melanoma, and key points for the boards.
May 23, 2022 • 14min
Thrombotic Thrombocytopenic Purpura (TTP)
Exploring Thrombotic Thrombocytopenic Purpura (TTP) including clinical characteristics, diagnosis, and causes. Discussions on the golden standard lab test, risk stratification, and treatment strategies for TTP and Hemolytic Uremic Syndrome (HUS).
May 16, 2022 • 16min
Kidney Cancer
A podcast on kidney cancer, covering risk factors, genetic conditions, staging, biopsy results, treatment options, clinical trials, restratification of metastatic RCC, cider reductive nephrectomy, treatment options for intermediate/poor risk RCC, double immunotherapy combo, epinevo vs. IOTKI, and veg FTKI side effects.
May 9, 2022 • 15min
Acute Myeloid Leukemia (AML)
This podcast episode discusses AML, including diagnosis, risk stratification, molecular testing, and treatment options. It also covers the importance of chemotherapy history, diagnostic criteria, and response assessment. Allogeneic stem cell transplant is discussed as a consideration for certain AML patients.
May 2, 2022 • 20min
Metastatic Colon Cancer
This podcast discusses the treatment options and sequencing for metastatic colon cancer, including chemotherapy backbones and regional preferences. It also covers the toxicities of full fox and full theory regimens, biomarker testing and targeted therapies, later lines of treatment and oligometastatic disease, and key points in treating metastatic colon cancer.
Apr 25, 2022 • 19min
Localized Colon Cancer
Learn about the stages of colon cancer, risk factors and syndromes associated with the disease. Explore the staging, treatment, and comparison of different chemotherapy options for high-risk stage 2 and stage 3 patients. Discover the results of a trial comparing three months versus six months of chemotherapy in adjuvant therapy for colon cancer.
Apr 18, 2022 • 14min
Immune Checkpoint Inhibitors
This podcast explores immune checkpoint inhibitors and how they enhance the body's ability to fight cancer. It discusses the success of immunotherapy in treating metastatic melanoma and the occurrence of pseudo progression. The podcast also covers the management of immune-related adverse events and highlights the potential life-threatening side effects of immune checkpoint inhibitors.
Apr 11, 2022 • 14min
Bladder Cancer
Pathology, presentation, diagnostics, staging, and treatment of bladder cancer. Workup process, treatment approaches, eligibility criteria for cisplatin treatment, bladder removal or preservation. Treatment options for metastatic bladder cancer, chemotherapy, immunotherapy, newer agents. Subtypes of urethhelial carcinoma, surgery for in situ cancer, upfront surgery for upper track carcinoma. Differentiating non-muscle invasive and muscle invasive bladder cancer, treatment options for metastatic urethhelial cancer.
